TRex Bio, Inc. announces its Q3 2026 financial results, showcasing advancements in its product pipeline and signaling growth in the biological products sector.
| Name | TRex Bio, Inc. |
|---|---|
| CIK | 0002139097 |
| Tickers | TRXB |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | <br>Emerging growth company |
| SIC | 2836 Biological Products, (No Diagnostic Substances) |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (650) 567-5582 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
TRex Bio, Inc. announces its Q3 2026 financial results, showcasing advancements in its product pipeline and signaling growth in the biological products sector.
TRex Bio, Inc. reveals significant stock transactions by Alexandria Venture Investments, LLC, indicating strategic shifts in ownership and investment.
TRex Bio, Inc. announces stock conversion as it prepares for IPO, impacting its ownership structure and the biological products industry.
TRex Bio, Inc. announces amendments to its articles of incorporation and a change in its fiscal year, signaling strategic adjustments in the biological products sector.
TRex Bio, Inc. grants stock options to director Peter Hirth, allowing him to purchase 17,500 shares at $14.00 each, reflecting the company's growth strategy.
TRex Bio, Inc. director Coy Travis Alan exercises stock options, signaling the company's commitment to talent retention in the biological products sector.
TRex Bio, Inc. grants stock options to Director Carol Giltner, reflecting commitment to leadership incentives in the Biological Products sector.
TRex Bio, Inc. has granted stock options to director Marcus Joel S, indicating a commitment to leadership incentives in the biological products industry.
TRex Bio, Inc. grants stock options to director Ross Michael Jay, reflecting a strategic move to incentivize leadership in the biological products industry.
TRex Bio, Inc. has filed an amended registration statement as it prepares for a potential public offering, signaling growth in the biological products sector.
40 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | 10-Q | 10-Q | 0001193125-26-460786 | 001-43501 | 261553163 | 34 | 9119130 | 1 | 1 | |
| 2026-11-13 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-460588 | 001-43501 | 261552303 | 34 | 399852 | 1 | 1 |
| 2026-10-16 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000078003-26-000118 | 005-95966 | 261467173 | 34 | 17925 | |||
| 2026-10-16 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0000059478-26-000095 | 005-95966 | 261466297 | 34 | 183893 | |||
| 2026-10-16 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0001829126-26-011242 | 005-95966 | 261465978 | 34 | 51479 | |||
| 2026-10-15 | 4 | FORM 4 | 0001722024-26-000004 | 10648 | ||||||
| 2026-10-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000904454-26-000517 | 005-95966 | 261462492 | 34 | 14105 | |||
| 2026-10-13 | 4 | 4 | 0001193125-26-420734 | 6966 | ||||||
| 2026-10-13 | 8-K | 8-K | 5.03,9.01 | 0001193125-26-420588 | 001-43501 | 261457486 | 34 | 440598 | 1 | 1 |
| 2026-10-13 | 4 | FORM 4 | 0001829126-26-011084 | 32902 | ||||||
| 2026-10-09 | S-8 | S-8 | 0001193125-26-419221 | 333-299406 | 261453745 | 33 | 355324 | 1 | 1 | |
| 2026-10-09 | 424B4 | 424B4 | 0001193125-26-419203 | 333-299018 | 261453583 | 33 | 36039764 | |||
| 2026-10-08 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-003188 | 333-299018 | 261451063 | 33 | 1791 | ||
| 2026-10-08 | 3 | FORM 3 | 0001829126-26-010932 | 16729 | ||||||
| 2026-10-08 | 4 | 4 | 0001193125-26-418302 | 5360 | ||||||
| 2026-10-08 | 4 | 4 | 0001193125-26-418298 | 5424 | ||||||
| 2026-10-08 | 4 | 4 | 0001193125-26-418296 | 5460 | ||||||
| 2026-10-08 | 4 | 4 | 0001193125-26-418293 | 5343 | ||||||
| 2026-10-08 | 4 | 4 | 0001193125-26-418292 | 5319 | ||||||
| 2026-10-08 | 4 | 4 | 0001193125-26-418291 | 5318 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418287 | 21898 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418286 | 19200 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418285 | 26215 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418283 | 5720 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418280 | 22244 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418279 | 20087 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418276 | 25310 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418274 | 24106 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418271 | 20449 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418270 | 21353 | ||||||
| 2026-10-08 | 3 | 3 | 0001193125-26-418269 | 22321 | ||||||
| 2026-10-08 | 3 | FORM 3 | 0000059478-26-000094 | 4599 | ||||||
| 2026-10-08 | 3 | FORM 3 | 0001722024-26-000002 | 5906 | ||||||
| 2026-10-08 | CERT | 8A_Cert_2139097.pdf | 0001354457-26-000964 | 001-43501 | 261449601 | 34 | 181540 | |||
| 2026-10-06 | 8-A12B | 8-A12B | 0001193125-26-415520 | 001-43501 | 261443897 | 34 | 33368 | |||
| 2026-10-05 | S-1/A | S-1/A | 0001193125-26-413060 | 333-299018 | 261438731 | 33 | 43295133 | 1 | 1 | |
| 2026-09-18 | S-1 | S-1 | 0001193125-26-395671 | 333-299018 | 261391568 | 33 | 38383518 | 1 | 1 | |
| 2026-08-21 | DRS/A | filename1.htm | 0001193125-26-361330 | 377-09512 | 261305861 | 33 | 36756094 | |||
| 2026-07-31 | DRS/A | filename1.htm | 0001193125-26-328889 | 377-09512 | 261229604 | 33 | 23574987 | |||
| 2026-06-26 | DRS | filename1.htm | 0001193125-26-285714 | 377-09512 | 261130486 | 33 | 20606580 |
One latest value per concept from companyfacts (122 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 28.79M | 2026-11-05 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 4,263.55 | 2026-10-08 | S-8 | 2026-10-09 | 0001193125-26-419221 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 4,263.55 | 2026-10-08 | S-8 | 2026-10-09 | 0001193125-26-419221 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 49.01M | 2026-10-08 | S-8 | 2026-10-09 | 0001193125-26-419221 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-08 | S-8 | 2026-10-09 | 0001193125-26-419221 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 13,810 | 2026-10-03 | S-1/A | 2026-10-05 | 0001193125-26-413060 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 1.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 1.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 8.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -151,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 2.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 5.20M | 2026-10-13 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 522,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 20.72M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | Assets | Assets | USD | 88.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 79.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 61.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 426,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 16.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 78.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 16.97M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 1.78M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 3.62M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 89.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 1.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 1.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -42.72M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | USD | 0 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 4.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | Depreciation | Depreciation | USD | 176,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | Dividends | Dividends | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -34.02 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -34.02 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 2.51M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 2.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 7.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -42.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 100,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 130,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 636,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncreaseDecreaseInAccruedIncomeTaxesPayable | Increase (Decrease) in Income Taxes Payable | USD | 128,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 2.79M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -848,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | 61,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | -1.86M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | InterestReceivable | Interest Receivable | USD | 300,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 2.52M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | LeaseCost | Lease, Cost | USD | 1.23M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 3.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 1.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 1.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 360,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | Liabilities | Liabilities | USD | 14.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 88.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 10.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | MarketableSecuritiesUnrealizedGainLoss | Marketable Securities, Unrealized Gain (Loss) | USD | -3,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 47.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -7.64M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -37.73M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -42.55M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NetRentableArea | Net Rentable Area | sqft | 33,780 | 2026-04-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 2.52M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segments | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segments | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 44.93M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -44.93M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 1.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 2.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 717,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 2.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 900,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 2.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 1.05M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 748,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 5.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | USD | -168,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OtherGeneralAndAdministrativeExpense | Other General and Administrative Expense | USD | 2.48M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 103,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -6,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OtherResearchAndDevelopmentExpense | Other Research and Development Expense | USD | 23.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | OtherSellingGeneralAndAdministrativeExpense | Other Selling, General and Administrative Expense | USD | 6.01M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 177,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 81.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 93,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 1.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 255,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 50.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 74.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 826,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 37.46M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 160,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -136.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 2.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 522,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 13.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 1.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 1.18 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 890,790 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 36.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 2.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 1.23 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 36.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | shares | 2.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | USD/shares | 1.23 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 1.19 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 1.28 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -134.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 216,139 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 149,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | StockIssuedDuringPeriodValueShareBasedCompensation | Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | USD | 178,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | TaxesPayableCurrentAndNoncurrent | Taxes Payable | USD | 1.30M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | TemporaryEquityParOrStatedValuePerShare | Temporary Equity, Par or Stated Value Per Share | USD/shares | 0 | 2026-01-31 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 68.57M | 2026-01-31 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 | |
| us-gaap | VariableLeaseCost | Variable Lease, Cost | USD | 130,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 1.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 1.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-13 | 0001193125-26-460786 |